Clinical Trial

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-07-16; most recent amendment 2026-07-16.
Trial Details
NCT Number NCT07082803
Lead Sponsor Treeline Biosciences, Inc.
Conditions Lymphoma, Lymphoma, Non Hodgkin
Enrollment 180 participants
Start Date 2025-06-23
Primary Completion 2030-09 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-20